UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Asporin is a stromally expressed marker associated with prostate cancer progression.

Rochette, A; Boufaied, N; Scarlata, E; Hamel, L; Brimo, F; Whitaker, HC; Ramos-Montoya, A; ... Thomson, AA; + view all (2017) Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer , 116 (6) pp. 775-784. 10.1038/bjc.2017.15. Green open access

bjc201715a.pdf - ["content_typename_Published version" not defined]

Download (2MB) | Preview


BACKGROUND: Prostate cancer shows considerable heterogeneity in disease progression and we propose that markers expressed in tumour stroma may be reliable predictors of aggressive tumour subtypes. METHODS: We have used Kaplan-Meier, univariate and multivariate analysis to correlate the expression of Asporin (ASPN) mRNA and protein with prostate cancer progression in independent cohorts. We used immunohistochemistry and H scoring to document stromal localisation of ASPN in a tissue microarray and mouse prostate cancer model, and correlated expression with reactive stroma, defined using Masson Trichrome staining. We used cell cultures of primary prostate cancer fibroblasts treated with serum-free conditioned media from prostate cancer cell lines to examine regulation of ASPN mRNA in tumour stromal cells. RESULTS: We observed increased expression of ASPN mRNA in a data set derived from benign vs tumour microdissected tissue, and a correlation with biochemical recurrence using Kaplan-Meier and Cox proportional hazard analysis. ASPN protein localised to tumour stroma and elevated expression of ASPN was correlated with decreased time to biochemical recurrence, in a cohort of 326 patients with a median follow up of 9.6 years. Univariate and multivariate analysis demonstrated that ASPN was correlated with progression, as were Gleason score, and clinical stage. Additionally, ASPN expression correlated with the presence of reactive stroma, suggesting that it may be a stromal marker expressed in response to the presence of tumour cells and particularly with aggressive tumour subtypes. We observed expression of ASPN in the stroma of tumours induced by p53 inhibition in a mouse model of prostate cancer, and correlation with neuroendocrine marker expression. Finally, we demonstrated that ASPN transcript expression in normal and cancer fibroblasts was regulated by conditioned media derived from the PC3, but not LNCaP, prostate cancer cell lines. CONCLUSIONS: Our results suggest that ASPN is a stromally expressed biomarker that correlates with disease progression, and is observed in reactive stroma. ASPN expression in stroma may be part of a stromal response to aggressive tumour subtypes.British Journal of Cancer advance online publication, 2 February 2017; doi:10.1038/bjc.2017.15 www.bjcancer.com.

Type: Article
Title: Asporin is a stromally expressed marker associated with prostate cancer progression.
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/bjc.2017.15
Publisher version: http://dx.doi.org/10.1038/bjc.2017.15
Language: English
Additional information: This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Keywords: Prostate cancer; tumour stroma; stromal markers; asporin
URI: http://discovery.ucl.ac.uk/id/eprint/1540341
Downloads since deposit
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item